Symbols / MOLN Stock $4.35 -2.46% Molecular Partners AG

Healthcare • Biotechnology • Switzerland • NMS
MOLN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Patrick Amstutz Ph.D.
Exch · Country NMS · Switzerland
Market Cap 162.74M
Enterprise Value 73.33M
Income -61.65M
Sales —
FCF (ttm) -27.53M
Book/sh 2.73
Cash/sh 2.49
Employees 134
Insider 10d —
IPO Jun 16, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -17.46
PEG —
P/S —
P/B 1.59
P/C —
EV/EBITDA -1.34
EV/Sales —
Quick Ratio 8.56
Current Ratio 8.79
Debt/Eq 4.54
LT Debt/Eq —
EPS (ttm) -2.10
EPS next Y -0.25
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-12
Earnings (prior) 2026-03-12
ROA -26.59%
ROE -55.55%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 37.41M
Shs Float 19.82M
Insider Own 0.00%
Instit Own 9.60%
Short Float 0.06%
Short Ratio 3.35
Short Interest 12.89K
52W High 5.36
vs 52W High -18.84%
52W Low 3.36
vs 52W Low 29.46%
Beta 0.74
Impl. Vol. —
Rel Volume 0.50
Avg Volume 3.41K
Volume 1.69K
Target (mean) $11.15
Tgt Median $12.04
Tgt Low $3.76
Tgt High $17.05
# Analysts 5
Recom Strong_buy
Prev Close $4.46
Price $4.35
Change -2.46%
About

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.15
Mean price target
2. Current target
$4.35
Latest analyst target
3. DCF / Fair value
$-13.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.35
Low
$3.76
High
$17.05
Mean
$11.15

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 reit HC Wainwright & Co. Buy → Buy $13
2026-03-16 reit HC Wainwright & Co. Buy → Buy $13
2026-01-27 init HC Wainwright & Co. — → Buy $13
2025-12-08 main JP Morgan Neutral → Neutral $4
2025-09-03 main JP Morgan Neutral → Neutral $4
2025-03-11 init LifeSci Capital — → Outperform $12
2023-12-05 main JP Morgan Neutral → Neutral $5
2022-08-29 down SVB Leerink Outperform → Market Perform $8
2022-05-25 up Credit Suisse Underperform → Neutral —
2022-04-27 main SVB Leerink — → Outperform $29
2022-01-14 main SVB Leerink — → Outperform $42
2021-08-27 main SVB Leerink — → Outperform $35
2021-07-13 init Cowen & Co. — → Outperform $50
News
RSS: Latest MOLN news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
4.97
-29.38%
7.04
-96.29%
189.56
Operating Revenue
0.00
-100.00%
4.97
-29.38%
7.04
-96.29%
189.56
Operating Expense
55.44
-16.24%
66.19
-2.87%
68.15
-6.58%
72.94
Research And Development
40.19
-17.30%
48.60
-0.37%
48.78
-3.87%
50.75
Selling General And Administration
14.87
-13.36%
17.16
-9.64%
19.00
-12.95%
21.82
General And Administrative Expense
14.87
-13.36%
17.16
-9.64%
19.00
-12.95%
21.82
Salaries And Wages
9.79
-10.71%
10.96
-5.83%
11.64
-1.26%
11.79
Other Gand A
5.08
-18.04%
6.20
-15.66%
7.36
-26.70%
10.03
Other Operating Expenses
—
—
—
-0.04
Total Expenses
55.44
-16.24%
66.19
-2.87%
68.15
-6.58%
72.94
Operating Income
-55.44
+9.44%
-61.22
-0.18%
-61.11
-152.40%
116.61
Total Operating Income As Reported
-58.12
+5.05%
-61.22
-0.18%
-61.11
-152.40%
116.61
EBITDA
-59.49
-15.18%
-51.65
+13.24%
-59.53
-149.26%
120.85
Normalized EBITDA
-51.78
+6.66%
-55.48
-1.93%
-54.42
-145.30%
120.13
Reconciled Depreciation
2.14
-9.50%
2.37
-2.11%
2.42
+1.34%
2.39
EBIT
-61.63
-14.10%
-54.02
+12.81%
-61.95
-152.30%
118.46
Total Unusual Items
-7.70
-301.10%
3.83
+175.01%
-5.11
-812.13%
0.72
Total Unusual Items Excluding Goodwill
-7.70
-301.10%
3.83
+175.01%
-5.11
-812.13%
0.72
Special Income Charges
-2.69
0.00
0.00
—
Restructuring And Mergern Acquisition
2.69
0.00
0.00
—
Net Income
-61.65
-14.08%
-54.04
+12.81%
-61.98
-152.59%
117.85
Pretax Income
-61.65
-14.08%
-54.04
+12.81%
-61.98
-152.59%
117.85
Net Non Operating Interest Income Expense
1.49
-55.50%
3.35
-20.90%
4.23
+708.80%
0.52
Interest Expense Non Operating
0.02
-28.00%
0.03
-26.47%
0.03
-94.38%
0.60
Net Interest Income
1.49
-55.50%
3.35
-20.90%
4.23
+708.80%
0.52
Interest Expense
0.02
-28.00%
0.03
-26.47%
0.03
-94.38%
0.60
Interest Income Non Operating
1.52
-55.02%
3.38
-20.92%
4.28
+274.69%
1.14
Interest Income
1.52
-55.02%
3.38
-20.92%
4.28
+274.69%
1.14
Other Income Expense
-7.70
-301.10%
3.83
+175.01%
-5.11
-812.13%
0.72
Gain On Sale Of Security
-5.01
-230.89%
3.83
+175.01%
-5.11
-812.13%
0.72
Tax Provision
0.00
+0.00%
0.00
0.00
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
-55.96%
0.00
-0.52%
0.00
Tax Effect Of Unusual Items
-0.65
-301.10%
0.33
+133.04%
-0.99
-808.46%
0.14
Net Income Including Noncontrolling Interests
-61.65
-14.08%
-54.04
+12.81%
-61.98
-152.59%
117.85
Net Income From Continuing Operation Net Minority Interest
-61.65
-14.08%
-54.04
+12.81%
-61.98
-152.59%
117.85
Net Income From Continuing And Discontinued Operation
-61.65
-14.08%
-54.04
+12.81%
-61.98
-152.59%
117.85
Net Income Continuous Operations
-61.65
-14.08%
-54.04
+12.81%
-61.98
-152.59%
117.85
Normalized Income
-54.60
+5.12%
-57.55
+0.55%
-57.86
-149.34%
117.28
Net Income Common Stockholders
-61.65
-14.08%
-54.04
+12.81%
-61.98
-152.59%
117.85
Diluted EPS
-1.65
-3.77%
-1.59
+15.87%
-1.89
-153.39%
3.54
Basic EPS
-1.65
-3.77%
-1.59
+15.87%
-1.89
-152.07%
3.63
Basic Average Shares
37.27
+9.52%
34.03
+3.85%
32.77
+0.93%
32.47
Diluted Average Shares
37.27
+9.52%
34.03
+3.85%
32.77
-1.49%
33.27
Diluted NI Availto Com Stockholders
-61.65
-14.08%
-54.04
+12.81%
-61.98
-152.59%
117.85
Depreciation Amortization Depletion Income Statement
0.37
-11.46%
0.42
+14.17%
0.37
-11.78%
0.42
Depreciation And Amortization In Income Statement
0.37
-11.46%
0.42
+14.17%
0.37
-11.78%
0.42
Total Other Finance Cost
0.01
+15.38%
0.01
-13.33%
0.01
+7.14%
0.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
102.11
-35.59%
158.53
-20.08%
198.35
Current Assets
96.88
-37.21%
154.28
-19.84%
192.46
Cash Cash Equivalents And Short Term Investments
93.06
-37.73%
149.44
-20.04%
186.89
Cash And Cash Equivalents
82.65
+29.40%
63.87
-5.10%
67.31
Cash Financial
82.65
+29.40%
63.87
-5.10%
67.31
Other Short Term Investments
10.40
-87.84%
85.56
-28.45%
119.58
Receivables
1.91
-26.53%
2.59
-15.92%
3.08
Accounts Receivable
0.25
-11.54%
0.29
-3.05%
0.29
Other Receivables
0.15
-56.94%
0.35
-70.51%
1.20
Taxes Receivable
1.50
-23.23%
1.95
+22.74%
1.59
Prepaid Assets
1.91
-14.90%
2.25
-9.53%
2.49
Other Current Assets
-0.00
—
—
Total Non Current Assets
5.23
+23.17%
4.25
-27.93%
5.89
Net PPE
5.23
+24.56%
4.20
-26.10%
5.68
Gross PPE
25.10
+11.75%
22.46
+2.00%
22.02
Accumulated Depreciation
-19.87
-8.81%
-18.27
-11.77%
-16.34
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
1.84
-16.91%
2.21
+8.75%
2.03
Other Properties
22.63
+15.36%
19.62
+1.35%
19.36
Leases
0.63
+0.00%
0.63
+0.00%
0.63
Goodwill And Other Intangible Assets
0.00
-95.92%
0.05
-76.89%
0.21
Other Intangible Assets
0.00
-95.92%
0.05
-76.89%
0.21
Other Non Current Assets
—
—
—
Total Liabilities Net Minority Interest
21.77
+28.90%
16.89
-22.95%
21.92
Current Liabilities
11.03
+2.24%
10.79
-25.19%
14.42
Payables And Accrued Expenses
9.82
+2.63%
9.57
+7.81%
8.88
Payables
1.77
-5.00%
1.86
+39.98%
1.33
Accounts Payable
0.94
+38.00%
0.68
+65.61%
0.41
Other Payable
0.83
-29.75%
1.18
+28.54%
0.92
Current Accrued Expenses
8.05
+4.48%
7.71
+2.15%
7.55
Employee Benefits
8.15
+66.98%
4.88
-3.63%
5.06
Total Tax Payable
—
—
—
Current Debt And Capital Lease Obligation
1.21
-0.90%
1.22
+0.75%
1.21
Current Capital Lease Obligation
1.21
-0.90%
1.22
+0.75%
1.21
Current Deferred Liabilities
—
0.00
-100.00%
4.33
Current Deferred Revenue
—
0.00
-100.00%
4.33
Other Current Liabilities
0.00
—
—
Total Non Current Liabilities Net Minority Interest
10.75
+75.99%
6.11
-18.66%
7.51
Long Term Debt And Capital Lease Obligation
2.44
+98.70%
1.23
-49.80%
2.44
Long Term Capital Lease Obligation
2.44
+98.70%
1.23
-49.80%
2.44
Tradeand Other Payables Non Current
0.16
0.00
—
Non Current Deferred Liabilities
—
—
0.00
Non Current Deferred Revenue
—
—
0.00
Other Non Current Liabilities
0.00
—
—
Stockholders Equity
80.33
-43.28%
141.64
-19.72%
176.43
Common Stock Equity
80.33
-43.28%
141.64
-19.72%
176.43
Capital Stock
4.04
+0.02%
4.04
+11.03%
3.63
Common Stock
4.04
+0.02%
4.04
+11.03%
3.63
Share Issued
40.37
+0.03%
40.36
+11.03%
36.35
Ordinary Shares Number
37.41
+1.49%
36.86
+12.20%
32.85
Treasury Shares Number
2.96
-15.34%
3.50
+0.00%
3.50
Additional Paid In Capital
389.18
+1.12%
384.88
+5.29%
365.53
Retained Earnings
-311.75
-26.58%
-246.29
-28.44%
-191.75
Gains Losses Not Affecting Retained Earnings
—
—
—
Treasury Stock
1.13
+15.09%
0.98
+0.00%
0.98
Other Equity Adjustments
—
—
—
Total Equity Gross Minority Interest
80.33
-43.28%
141.64
-19.72%
176.43
Total Capitalization
80.33
-43.28%
141.64
-19.72%
176.43
Working Capital
85.85
-40.17%
143.50
-19.40%
178.04
Invested Capital
80.33
-43.28%
141.64
-19.72%
176.43
Total Debt
3.64
+49.10%
2.44
-33.08%
3.65
Capital Lease Obligations
3.64
+49.10%
2.44
-33.08%
3.65
Net Tangible Assets
80.33
-43.26%
141.59
-19.65%
176.22
Tangible Book Value
80.33
-43.26%
141.59
-19.65%
176.22
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-51.26
+13.49%
-59.25
-0.41%
-59.01
-149.77%
118.57
Cash Flow From Continuing Operating Activities
-51.26
+13.49%
-59.25
-0.41%
-59.01
-149.77%
118.57
Net Income From Continuing Operations
-61.65
-14.08%
-54.04
+12.81%
-61.98
-152.59%
117.85
Depreciation Amortization Depletion
2.14
-9.50%
2.37
-2.11%
2.42
+1.34%
2.39
Depreciation
2.10
-4.16%
2.19
+2.82%
2.13
—
Amortization Cash Flow
0.05
-74.59%
0.18
-38.01%
0.29
—
Depreciation And Amortization
2.14
-9.50%
2.37
-2.11%
2.42
+1.34%
2.39
Amortization Of Intangibles
0.05
-74.59%
0.18
-38.01%
0.29
—
Other Non Cash Items
3.18
+144.28%
-7.19
-934.84%
0.86
+168.66%
-1.25
Pension And Employee Benefit Expense
-0.55
+18.51%
-0.67
-225.23%
0.54
-53.36%
1.15
Stock Based Compensation
4.42
+7.65%
4.11
-21.16%
5.21
+2.34%
5.09
Deferred Tax
0.00
+0.00%
0.00
0.00
0.00
Deferred Income Tax
0.00
+0.00%
0.00
0.00
0.00
Operating Gains Losses
-0.55
+18.51%
-0.67
-225.23%
0.54
-53.36%
1.15
Change In Working Capital
1.21
+131.87%
-3.80
+36.82%
-6.01
+0.00%
-6.01
Change In Receivables
0.48
+239.77%
-0.35
+62.81%
-0.93
-103.69%
25.26
Change In Prepaid Assets
—
—
—
—
Change In Payables And Accrued Expense
0.41
-40.44%
0.69
+189.31%
-0.77
+90.13%
-7.77
Change In Accrued Expense
0.34
+113.04%
0.16
+257.78%
0.04
+101.85%
-2.43
Change In Payable
0.07
-87.60%
0.52
+164.53%
-0.81
+84.79%
-5.34
Change In Account Payable
—
0.52
+164.53%
-0.81
+84.79%
-5.34
Change In Other Working Capital
-0.02
+99.59%
-4.37
+23.75%
-5.73
+77.33%
-25.29
Change In Other Current Assets
0.34
+41.35%
0.24
-83.36%
1.42
-20.31%
1.79
Investing Cash Flow
72.55
+79.20%
40.49
-9.30%
44.64
+144.14%
-101.12
Cash Flow From Continuing Investing Activities
72.55
+79.20%
40.49
-9.30%
44.64
+144.14%
-101.12
Net PPE Purchase And Sale
-0.71
-1.28%
-0.70
-22.61%
-0.57
+51.15%
-1.18
Purchase Of PPE
-0.71
-1.28%
-0.70
-22.61%
-0.57
+51.15%
-1.18
Capital Expenditure
-0.71
+1.24%
-0.72
+10.52%
-0.81
+42.98%
-1.42
Net Investment Purchase And Sale
71.54
+93.50%
36.97
-11.17%
41.62
+141.54%
-100.20
Purchase Of Investment
-66.28
+72.39%
-240.04
+13.60%
-277.82
+7.21%
-299.42
Sale Of Investment
137.81
-50.25%
277.01
-13.28%
319.44
+60.35%
199.22
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.02
+92.27%
-0.23
+2.92%
-0.24
Purchase Of Intangibles
0.00
+100.00%
-0.02
+92.27%
-0.23
+2.92%
-0.24
Financing Cash Flow
-1.15
-107.96%
14.43
+1336.76%
-1.17
+25.67%
-1.57
Cash Flow From Continuing Financing Activities
-1.15
-107.96%
14.43
+1336.76%
-1.17
+25.67%
-1.57
Net Issuance Payments Of Debt
-1.21
-0.33%
-1.21
-0.83%
-1.20
-0.76%
-1.19
Repayment Of Debt
-1.21
-0.33%
-1.21
-0.83%
-1.20
-0.76%
-1.19
Long Term Debt Payments
-1.21
-0.33%
-1.21
-0.83%
-1.20
-0.76%
-1.19
Net Long Term Debt Issuance
-1.21
-0.33%
-1.21
-0.83%
-1.20
-0.76%
-1.19
Net Common Stock Issuance
0.00
-100.00%
17.34
0.00
+100.00%
-0.63
Common Stock Payments
—
0.00
0.00
+100.00%
-0.63
Repurchase Of Capital Stock
—
0.00
0.00
+100.00%
-0.63
Proceeds From Stock Option Exercised
0.06
+57.50%
0.04
+29.03%
0.03
-87.60%
0.25
Net Other Financing Charges
—
-1.74
—
—
Changes In Cash
20.14
+565.30%
-4.33
+72.13%
-15.54
-197.86%
15.88
Effect Of Exchange Rate Changes
-1.36
-252.57%
0.89
+117.52%
-5.10
-2077.52%
0.26
Beginning Cash Position
63.87
-5.10%
67.31
-23.47%
87.95
+22.47%
71.81
End Cash Position
82.65
+29.40%
63.87
-5.10%
67.31
-23.47%
87.95
Free Cash Flow
-51.97
+13.34%
-59.97
-0.26%
-59.81
-151.06%
117.15
Common Stock Issuance
0.00
-100.00%
17.34
0.00
0.00
Interest Paid CFO
-0.02
+30.77%
-0.03
+23.53%
-0.03
+94.74%
-0.65
Interest Received CFI
1.73
-59.26%
4.24
+10.77%
3.83
+674.70%
0.49
Issuance Of Capital Stock
0.00
-100.00%
17.34
0.00
0.00
Taxes Refund Paid
—
0.00
0.00
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category